FDA has already been in the news recently for suppressing the scientific evidence observing an increased risk of suicidality in youth using antidepressants and, more recently, for suppressing internal agency documents that may detail FDA's bungling of the flu vaccine supply. Now the NY Times is reporting that internal FDA emails suggest FDA actually delayed the study showing deadly problems with Merck's COX-2 inhibitor drug Vioxx: